what do the latest guidelines day on treatment of arteriyel hypertension

Management of arterial hypertension involves a combination of accurate diagnosis, lifestyle modification, pharmacological treatment, and ongoing monitoring to reduce cardiovascular risk and prevent hypertension-mediated organ damage (HMOD).

Diagnosis and Initial Assessment: Hypertension is confirmed by persistently elevated blood pressure readings, with clinic measurements ≥140/90 mmHg followed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) to verify the diagnosis. Classification by severity guides management: stage 1 (140/90 to 159/99 mmHg clinic BP), stage 2 (160/100 to 179/119 mmHg), and stage 3 or severe hypertension (≥180/120 mmHg). Assessment should include screening for secondary causes, HMOD via ECG, blood and urine tests for kidney function, and cardiovascular risk evaluation. Referral for specialist assessment is indicated urgently in cases of accelerated hypertension or life-threatening symptoms NICE CKS,NICE NG136,Gerdts et al. 2026 Writing Committee Members* et al. 2025 Lee et al. 2026.

Lifestyle Modifications: All patients should receive lifestyle advice including dietary sodium reduction, alcohol moderation, increased physical activity, smoking cessation (including e-cigarettes), stress reduction techniques such as mindfulness and breathing exercises, and weight management. These interventions lower BP and improve overall cardiovascular health NICE CKS,NICE NG136,Gerdts et al. 2026 Lee et al. 2026.

Pharmacological Treatment: Drug therapy is recommended based on hypertension stage, cardiovascular risk, age, and comorbidities. Antihypertensive options include ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide-like diuretics, initiated stepwise with preference for once-daily dosing and single-pill combinations where possible to improve adherence NICE CKS,NICE NG136,NICE CKS,Gerdts et al. 2026.

For adults under 80 years and with persistent stage 1 hypertension, drug treatment is advised if there is target organ damage, established cardiovascular or renal disease, diabetes, or ≥10% 10-year cardiovascular risk; for stage 2 hypertension, drug treatment is recommended regardless of risk NICE NG136. For adults over 80, clinical judgment guides initiation, with higher BP targets tolerated NICE CKS,NICE NG136.

Specific recommendations for pharmacotherapy include initial treatment with ACE inhibitors or ARBs, except in people of African or Caribbean descent, who may benefit more from ARBs or CCBs. If BP remains uncontrolled, a choice of adding a CCB or diuretic is advised, followed by triple therapy combining ACEi/ARB, CCB, and diuretic. Resistant hypertension—uncontrolled on triple therapy at optimal doses—warrants consideration of fourth-line agents like spironolactone or amiloride, and may prompt specialist referral NICE NG136,NICE CKS,Gerdts et al. 2026.

Newer therapeutic agents integrated into recent guidelines include angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and aldosterone synthase inhibitors for selected patients, such as those with resistant hypertension, heart failure, chronic kidney disease, or diabetes, offering cardiovascular and renal protective benefits beyond BP lowering Gerdts et al. 2026.

Blood Pressure Targets: Clinic BP targets are <140/90 mmHg for adults under 80 years and <150/90 mmHg for those over 80, with ambulatory or home BP targets correspondingly lower (<135/85 mmHg and <145/85 mmHg). In high-risk populations (e.g., diabetes, chronic kidney disease, established cardiovascular disease), intensive BP control to <130/80 mmHg is recommended if tolerated. In some specialized groups (e.g., older adults with high cardiovascular risk), even lower systolic targets around 120 mmHg may be considered with caution to avoid hypotension NICE CKS,NICE NG136,Gerdts et al. 2026 Shamsulddin AB 2026 Lee et al. 2026.

Monitoring and Follow-up: Annual reviews should include BP measurement, assessment of medication adherence, review of side effects, and reinforcement of lifestyle changes. Home or ambulatory BP monitoring is encouraged to detect white-coat or masked hypertension and to better guide therapy NICE CKS,NICE NG136,Gerdts et al. 2026.

Special Populations and Considerations: For adults under 40, specialist evaluation for secondary hypertension is recommended. Pregnant women should be managed with careful BP control (<140/90 mmHg) using agents considered safe in pregnancy such as labetalol, methyldopa, nifedipine, or amlodipine, with out-of-office BP monitoring preferred to improve diagnostic accuracy. In resistant hypertension, exclusion of pseudo-resistance, assessment of adherence, screening for secondary causes, and consideration of advanced therapies like renal sympathetic denervation are integral parts of management NICE CKS,NICE NG136,Gerdts et al. 2026 Lee et al. 2026.

Hypertension-Mediated Organ Damage Assessment: Screening for organ damage (heart, kidney, eyes, brain, arteries) is essential for risk stratification. Basic assessments such as ECG and kidney function tests should be performed in all patients, while advanced imaging and arterial stiffness measurements may be considered selectively to tailor management NICE CKS,Gerdts et al. 2026 Gerdts et al. 2026.

Summary: The latest clinical guidelines recommend a patient-centered, stepwise approach to hypertension management that integrates accurate diagnosis, individualized risk assessment, lifestyle interventions, tailored pharmacotherapy including newer agents, and vigilant monitoring of blood pressure and organ damage. Blood pressure targets are individualized based on age, comorbidities, and risk, emphasizing intensive control in high-risk and selected populations while avoiding overtreatment in frail elderly patients NICE CKS,NICE NG136,NICE CKS,Gerdts et al. 2026 Shamsulddin AB 2026 Lee et al. 2026.